CD44 and breast cancer: To this end, we have previously reported that acquired tamoxifen resistance in breast cancer is accompanied by the overexpression of the CD44 transmembrane receptor protein that appears to contribute to their aggressive phenotype through modulation of growth factor receptor signaling.